Bank of New York Mellon Corp Lowers Position in Veru Inc. (NASDAQ:VERU)

Bank of New York Mellon Corp trimmed its stake in shares of Veru Inc. (NASDAQ:VERU) by 8.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 316,041 shares of the company’s stock after selling 27,781 shares during the period. Bank of New York Mellon Corp’s holdings in Veru were worth $206,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Weaver Consulting Group increased its stake in Veru by 41.0% in the 4th quarter. Weaver Consulting Group now owns 69,705 shares of the company’s stock worth $45,000 after acquiring an additional 20,280 shares during the last quarter. Gladstone Institutional Advisory LLC grew its holdings in shares of Veru by 52.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 86,876 shares of the company’s stock valued at $57,000 after purchasing an additional 30,000 shares in the last quarter. Zacks Investment Management bought a new stake in Veru in the third quarter worth $25,000. Jane Street Group LLC raised its stake in Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock valued at $74,000 after purchasing an additional 56,736 shares in the last quarter. Finally, PVG Asset Management Corp lifted its position in Veru by 13.1% during the third quarter. PVG Asset Management Corp now owns 636,970 shares of the company’s stock valued at $490,000 after purchasing an additional 73,815 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

Veru Price Performance

NASDAQ:VERU opened at $0.51 on Friday. The firm has a market capitalization of $74.38 million, a price-to-earnings ratio of -1.95 and a beta of -0.46. The business has a 50 day simple moving average of $0.60 and a 200-day simple moving average of $0.70. Veru Inc. has a 1 year low of $0.45 and a 1 year high of $1.92.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. As a group, analysts expect that Veru Inc. will post -0.22 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Veru news, Director Michael L. Rankowitz purchased 95,279 shares of Veru stock in a transaction dated Tuesday, February 18th. The shares were purchased at an average cost of $0.55 per share, for a total transaction of $52,403.45. Following the completion of the acquisition, the director now owns 195,279 shares in the company, valued at $107,403.45. This represents a 95.28 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $3.00 target price on shares of Veru in a report on Thursday, January 2nd.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.